



(43) International Publication Date
4 October 2012 (04.10.2012)

(10) International Publication Number
WO 2012/134520 A4

(51) International Patent Classification:
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2011/049696

(22) International Filing Date:
30 August 2011 (30.08.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/378,450 31 August 2010 (31.08.2010) US

(71) Applicant (for all designated States except US): **SAMI LABS LIMITED** [IN/IN]; 19/1 & 19/2 I Main II Phase, Peenya Industrial Estate/Area, Bangalore 560058 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MAJEED, Muhammed** [US/US]; Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ 08520 (US). **NAGABHUSHANAM, Kalyanam** [US/US]; Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ 08520 (US). **PANDEY, Anjali** [IN/IN]; Sami Labs Limited, 19/1 & 19/2 I Main II Phase, Peenya Industrial Estate/Area, Bangalore 560058 (IN). **RANGANATH, Shivakumar** [IN/IN]; Sami Labs Limited, 19/1 & 19/2 I Main II Phase, Peenya Industrial Estate/Area, Bangalore 560058 (IN).

(74) Common Representative: **NAGABHUSHANAM, Kalyanam**; Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ 08520 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with amended claims and statement (Art. 19(1))

(88) Date of publication of the international search report:
7 February 2013

Date of publication of the amended claims and statement: 21
March 2013

(54) Title: REGULATION OF IMMUNE RESPONSE BY COLOCYNTHIN AND/OR ITS DERIVATIVES

(57) Abstract: The present invention relates to a method of inhibiting pro-inflammatory and T-cell mediated cytokines, said method comprising step of administering to a subject in need thereof a therapeutically effective amount of colocynthin and/or its derivatives. The invention also relates to a method of inhibiting T-cell surface markers and to a method of regulating immune response by colocynthin and/or its derivatives.



WO 2012/134520 A4

AMENDED CLAIMS

received by the International Bureau on 27 October 2012 (27.10.2012)

3. A method of inhibiting T-cell mediated cytokines IL-2, IFN- γ and IL-4, said method comprising step of administering to a subject in need thereof therapeutically effective amount of colocyntin and/or its derivatives.
4. A method of inhibiting T-cell surface markers, said method comprising step of contacting the T-cell or administering to a subject in need thereof therapeutically effective amount of colocyntin and/or its derivatives.
5. The method as claimed in claim 4, wherein the T-cell surface markers are CD4 and CD8.

STATEMENT UNDER ARTICLE 19 (1)

As filed Claim 3 was dependant on Claim 1. In view of the ISR & WO, Claims 1, 2 and 6 have been cancelled through this response. Since the WO has mentioned that Claim 3 meets the criteria set out under PCT Art.33 (2)-(3) because the prior art does not teach or fairly suggest the claimed invention, Claim 3 is made an independent claim retaining intact its inventive features as such. Amendment to Claim 3 does not introduce subject matter that extends beyond the content of the disclosure of the as filed International application. Claims 4 and 5 are retained as such without any amendments.